A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs Abstract #1881

Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).
Aim(s): Evaluate whether including molecular information increases the predictive accuracy of a clinical nomogram for PFS in small bowel NETs.
Materials and methods: Small bowel NETs (n=84) median follow-up 22 months. Clinical history including age (median: 65 years), gender (43M), grade (NET G1: 60, NET G2: 24), stage (CS: I-IV), functional status, surgery, CgA and SSA use were used. Blood transcript levels (n=51) measured by QRT-PCR (scaled 0-100%). Outcome was PFS (RECIST). Mann-Whitney, McNemar, Kaplan-Meier and Cox-proportional modeling.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Mark Kidd

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1569 Blood Measurement of NET Transcripts (NETest) Predicts Well-Differentiated Gastroenteropancreatic NET Disease Status and Is Prognostic for Disease Progression
Introduction: A key issue in GEP-NETs is early identification and prediction of disease progression. Clinical evaluation and imaging are limited due to the lack of sensitivity and disease indolence.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Pavel M, Jann H, Prasad V, Drozdov I, ...
Keywords: PCR
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#2273 The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Follow-up after resection of pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence early, as incidence is reported up to 48%.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: M.D. Cansu Genc